<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="are few studies that have investigated predictive factors related to" exact="migraine" post="prophylaxis of which produced inconsistent results. The aim of"/>
 <result pre="a reduction of more than 50% in the number of" exact="migraine" post="episodes after topiramate treatment. Proposed predictive factors such as"/>
 <result pre="migraine episodes after topiramate treatment. Proposed predictive factors such as" exact="migraine" post="characteristics including severity and frequency were assessed, as were"/>
 <result pre="treatment ( p=0.004). Sex, the severity, frequency, and duration of" exact="migraine" post="episodes, disease duration, treatment duration, age at onset, and"/>
 <result pre="topiramate treatment should be strongly encouraged in this patient group." exact="migraine" post="predictive factor prophylaxis topiramate INTRODUCTION Headache is one of"/>
 <result pre="females when reaching adolescence. 2 3 4 The prevalence of" exact="migraine" post="among school children was reported to be 8.7% in"/>
 <result pre="with their academic achievement and social interaction. 6 Treatment of" exact="migraine" post="includes lifestyle modification and acute abortive or prophylactic treatment"/>
 <result pre="on this background, the present study investigated the characteristics of" exact="migraine" post="and associated symptoms with the aim of identifying the"/>
 <result pre="University Bundang Hospital (SNUBH) (IRB No. B-1511-324-11). Patients diagnosed with" exact="migraine" post="at SNUBH between January 2005 and December 2014 were"/>
 <result pre="reasons other than a headache, 3) receiving additional medication for" exact="migraine" post="prophylaxis within 3 months after starting topiramate prophylaxis, and"/>
 <result pre="associated symptoms) in any first-degree relative was consistent with a" exact="migraine" post="diagnosis. The associated symptoms taken into account included nausea,"/>
 <result pre="being present when the patient complained about dizziness associated with" exact="migraine" post="and when there was no vertigo or other neurological"/>
 <result pre="recommendations. 16 17 18 Patients who experienced fewer than 10" exact="migraine" post="episodes per month but still suffered from severe disturbance"/>
 <result pre="in increments of 50% of the previous dosage if the" exact="migraine" post="frequency was not reduced by 50%. Any increase in"/>
 <result pre="duration was longer in the nonresponder group (20.3±18.2 months) before" exact="migraine" post="prophylaxis than in the responder group (15.5±14.0 months), but"/>
 <result pre="the nonresponder group (72.9% vs. 53.5%, p=0.035). Family history of" exact="migraine" post="was not significantly different between the two groups [nonresponder"/>
 <result pre="( p=0.004) ( Table 2). DISCUSSION We analyzed demographic features," exact="migraine" post="characteristics, and associated symptoms with the aim of determining"/>
 <result pre="these factors were associated with topiramate prophylaxis response in pediatric" exact="migraine" post="patients. The presence of associated symptoms such as nausea,"/>
 <result pre="different studies. However, most studies found no significant relationship with" exact="migraine" post="prophylaxis. Impairment of daily activities was significantly more common"/>
 <result pre="lack of clarity of the relationship between predictive factors of" exact="migraine" post="and response to prophylaxis, with most factors not being"/>
 <result pre="being related to the treatment response. We also confirmed that" exact="migraine" post="characteristics and associated symptoms individually were not related to"/>
 <result pre="patients with severe headache and many associated symptoms perceive their" exact="migraine" post="as being more severe. Therefore, these patients and even"/>
 <result pre="these findings could even improve their treatment compliance. Characteristics of" exact="migraine" post="such as duration and location differ between children and"/>
 <result pre="children and adults. 25 26 In addition, symptoms associated with" exact="migraine" post="experienced by children can differ between different age groups."/>
 <result pre="different age groups. 27 Therefore, applying study results for adult" exact="migraine" post="to the pediatric population has limitations. To the best"/>
 <result pre="often not been considered. Dizziness is experienced by 50–60% of" exact="migraine" post="patients, and hence is one of the most common"/>
 <result pre="that the findings might not be applicable to all pediatric" exact="migraine" post="patients. In addition, only the associated symptoms included in"/>
 <result pre="for elucidating predictive factors more precisely. This study found that" exact="migraine" post="characteristics and associated symptoms were not related to the"/>
 <result pre="and a clinical, psychological and electroencephalographic comparison between children with" exact="migraine" post="and matched controls Acta Paediatr Suppl 1962 136 1"/>
 <result pre="Headache 2012 52 327 332 22288386 3 Lewis DW Pediatric" exact="migraine" post="Neurol Clin 2009 27 481 501 19289227 4 Abu-Arefeh"/>
 <result pre="19289227 4 Abu-Arefeh I Russell G Prevalence of headache and" exact="migraine" post="in schoolchildren BMJ 1994 309 765 769 7950559 5"/>
 <result pre="592 599 21929660 6 Stang PE Osterhaus JT Impact of" exact="migraine" post="in the United States: data from the National Health"/>
 <result pre="29 35 8436495 7 Wasiewski WW Preventive therapy in pediatric" exact="migraine" post="J Child Neurol 2001 16 71 78 11292228 8"/>
 <result pre="trial of propranolol versus sodium valproate for the prophylaxis of" exact="migraine" post="in pediatric patients Paediatr Drugs 2010 12 269 275"/>
 <result pre="S Uyar M et al. Sodium valproate prophylaxis in childhood" exact="migraine" post="Headache 2002 42 819 822 12390647 12 Winner P"/>
 <result pre="Hulihan J collab: Topiramate Pediatric Migraine Study Investigators Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial Headache"/>
 <result pre="study to evaluate the efficacy and safety of topiramate for" exact="migraine" post="prevention in pediatric subjects 12 to 17 years of"/>
 <result pre="M Christie SN et al. Canadian Headache Society guideline for" exact="migraine" post="prophylaxis Can J Neurol Sci 2012 39 2 Suppl"/>
 <result pre="39 2 Suppl 2 S1 S59 18 Silberstein SD Preventive" exact="migraine" post="treatment Continuum (Minneap Minn) 2015 21 973 989 26252585"/>
 <result pre="Pavese N Gambaccini G Rossi G Bonuccelli U Flunarizine in" exact="migraine" post="prophylaxis: predictive factors for a positive response Cephalalgia 1998"/>
 <result pre="9731940 20 Rossi P Fiermonte G Pierelli F Cinnarizine in" exact="migraine" post="prophylaxis: efficacy, tolerability and predictive factors for therapeutic responsiveness."/>
 <result pre="C Wöber-Bingöl C Koch G Wessely P Long-term results of" exact="migraine" post="prophylaxis with flunarizine and beta-blockers Cephalalgia 1991 11 251"/>
 <result pre="trial of acupuncture versus topiramate treatment in patients with chronic" exact="migraine" post="Clin J Pain 2013 29 982 987 23370087 24"/>
 <result pre="Caers LI Aerts TJ Flunarizine, a calcium entry blocker in" exact="migraine" post="prophylaxis Headache 1985 25 249 254 3897128 25 Raieli"/>
 <result pre="Eidlitz-Markus T Gorali O Haimi-Cohen Y Zeharia A Symptoms of" exact="migraine" post="in the paediatric population by age group Cephalalgia 2008"/>
 <result pre="Prevalence of vertigo, dizziness, and migrainous vertigo in patients with" exact="migraine" post="Headache 2007 47 1427 1435 18052952 30 Noseda R"/>
 <result pre="Diamond S Diamond ML Reed M Prevalence and burden of" exact="migraine" post="in the United States: data from the American Migraine"/>
 <result pre="Koerte I Straube A et al. Associations between stress and" exact="migraine" post="and tension-type headache: results from a school-based study in"/>
 <result pre="Sostak P Reinisch VM Noachtar S et al. Headache in" exact="juvenile myoclonic epilepsy" post="J Headache Pain 2011 12 227 233 21437711 37"/>
 <result pre="Reinisch VM Noachtar S et al. Headache in juvenile myoclonic" exact="epilepsy" post="J Headache Pain 2011 12 227 233 21437711 37"/>
 <result pre="Sartori S Salviati L et al. Comorbidity between headache and" exact="epilepsy" post="in a pediatric headache center J Headache Pain 2010"/>
 <result pre="and clinical characteristics as predictive factors of the response to" exact="migraine" post="prophylaxis using topiramate Total ( n=113) Responders ( n=70)"/>
</results>
